Skip to main content
SpringerLink
Log in

Primary Osteoporosis in Conditions of Pediatric Onset

  • Chapter
  • First Online:
Osteoporosis Rehabilitation

  • 904 Accesses

Abstract

In the past, osteoporosis has been regarded as a disease of elderly women or of adults with diseases that cause progressive bone loss and fragility fractures. More recently, physicians and researchers have become aware of conditions that lead to low bone mineral density (BMD) and fractures not only in childhood and adolescence but later in life. Diseases and disorders originating in childhood but with implications for adulthood fall into two categories: primary bone and joint diseases and secondary bone diseases. This chapter will focus on primary osteoporosis, particularly osteogenesis imperfecta, as well as one condition with direct effects on joints and indirect effects on bone, specifically juvenile idiopathic arthritis. Other childhood diseases—spina bifida and the eating disorders, amenorrhea, and osteoporosis that constitute the female athlete triad—are considered elsewhere in this volume. What is common to all is the fact that they have their onset in childhood, leading to osteoporosis by or before young adulthood so that by their mid-20s and mid-30s, patients have the bones of a 70–80-year-old. Compromised bone health from infancy to age 19 carries a lifetime risk of osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Laine C, Laine T. Diagnosis of osteoporosis in children and adolescents. Eur Endocrinol. 2013;9(2):141–4.

    Google Scholar 

  2. Langman CB, Trippe KA. Osteoporosis in children and adolescents. Osteoporosis clinical updates. Washington, DC: National Osteoporosis Foundation; 2010.

    Google Scholar 

  3. Gafni RI, Baron J. Overdiagnosis of osteoporosis in children due to misinterpretation of dual-energy x-ray absorptiometry (DEXA). J Pediatr. 2004;144(200):253–7.

    Article  PubMed  Google Scholar 

  4. Bachrach LK. Bone densitometry in children and adolescents. Pediatrics. 2011;127(1):189–94.

    Article  PubMed  Google Scholar 

  5. Binkovitz LA, Henwood MJ. Pediatric DXA: technique and interpretation. Pediatr Radiol. 2007;37(1):21–31.

    Article  PubMed  Google Scholar 

  6. International Society for Clinical Densitometry. ICSD official position—pediatric—skeletal health assessment in children from infancy to adolescence. Middletown; 2013. http://www.iscd.org/official-positions/2013-iscd-official -positions-pediatric. Accessed 22 Dec 2015.

  7. Marini JC. Osteogenesis imperfecta. In: Rosen CJ, editor. Primer on metabolic bone diseases and disorders of mineral metabolism. Ames: Wiley; 2013. p. 822–9.

    Chapter  Google Scholar 

  8. National Institute of Arthritis and Musculoskeletal and Skin Diseases. What people with osteogenesis imperfecta need to know about osteoporosis. NIH Osteoporosis and Related Bone Diseases-National Resource Center; 2012. http://www.niams.nih.gov/Health_Info/Bone/Osteoporosis/Conditions_Behaviors/osteoporosis. Accessed 10 Aug 2015.

  9. Bishop N, Glorieux FH. Juvenile osteoporosis. In: Rosen CJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Ames: Wiley; 2013. p. 468–72.

    Chapter  Google Scholar 

  10. Osteogenesis Imperfecta Foundation. OI issues: understanding type 1 OI. Gaithersburg; 2006. http://www.oif.org/sute/PageServer?pagename= Type 1. Accessed 9 Aug 2015.

  11. National Institutes of Health. Guide to osteogenesis imperfecta for pediatricians and family physicians. Osteoporosis and Related Bone Diseases-National Resource Center, Bethesda. 2007. www.niams.nih.gov/Health_Info/Bone/default.asp. Accessed 10 Aug 2015.

  12. National Osteoporosis Foundation. Facts about Osteogenesis Imperfecta. www.oif.org. Accessed 13 Feb 2016.

  13. Osteogenesis Imperfecta Foundation. Linked clinical research centers. http://www.oi.org/site/PageServer?pagename=RS_lcrc. Accessed 15 Aug 2015.

  14. National Institute of Arthritis and Musculoskeletal and Skin Diseases. OI issues: type I—understanding the mildest form of osteogenesis imperfecta. Bethesda; 2012. http://niams.nih.gov/Health_Info/Bone/Osteogenesis_Imperfecta/type_1/asp. Accessed 15 Aug 2015.

  15. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363(9418):1377–85.

    Article  CAS  PubMed  Google Scholar 

  16. Green DW. Osteogenesis imperfecta: a multidisciplinary approach to treatment in children. Hospital for Special Surgery; 2011. http://www.hss.edu/conditions_osteogenesis-imperfecta-approach-to-treatment.asp. Accessed 15 Aug 2015.

  17. Zacharin M, Kanumakaia S. Pamidronate treatment of less severe forms of osteogenesis imperfecta in children. J Pediatr Endocrinol Metab. 2004;17(11):1511–8.

    Article  CAS  PubMed  Google Scholar 

  18. Brown JJ, Zacharin MR. Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. J Pediatr Endocrinol Metab. 2009;22(1):225–7.

    Article  Google Scholar 

  19. DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res. 2006;21(12):132–40.

    PubMed  Google Scholar 

  20. Ward LM, Petryk A, Gordon CM. Use of bisphosphonates in the treatment of pediatric osteoporosis. Int J Clin Rheumatol. 2009;4(6):657–72.

    Article  CAS  Google Scholar 

  21. Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2014;7. doi:10.1002/14651858.CD005088.

  22. Hald JD, Evangelou E, Langdahl BL, Ralston SH. Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials. J Bone Miner Res. 2015;30(5):929–33.

    Article  CAS  PubMed  Google Scholar 

  23. Marini JC. Bone: use of bisphosphonates in children—proceed with caution. Nat Rev Endocrinol. 2009;5:241–2. doi:10.1038/nrendo.2009.58.

    Article  CAS  PubMed  Google Scholar 

  24. Brizola E, Shapiro JR. Bisphosphonate treatment of children and adults with osteogenesis imperfecta: unanswered questions. Calcif Tissue Int. 2015;97(2):101–3. doi:10.1007/s00223-015-0021-6.

    Article  CAS  PubMed  Google Scholar 

  25. Rijks EBG, Bongers BC, Vlemmix MJL, Boot AM, van Dijk ATH, Sakkers RJB, et al. Efficacy and safety of bisphosphonate therapy in children with osteogenesis imperfecta: a systematic review. Horm Res Paediatr. 2015;84(1):26–42.

    Article  CAS  PubMed  Google Scholar 

  26. Palomo T, Fassier F, Ouellet J, Sato A, Montpetit K, Glorieux FH, et al. Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years. J Bone Miner Res. 2015;30(12):2150–7.

    Article  CAS  PubMed  Google Scholar 

  27. Hoyer-Kuhn H, Franklin J, Allo G, Kron H, Netzer C, Eysel P, et al. Safety and efficacy of denosumab in children with osteogenesis imperfecta—a first prospective trial. J Musculoskelet Neuronal Interact. 2016;16(1):24–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011;7(9):540–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Dogba MJ, Rauch F, Wong T, Ruck J, Glorieux FH, Bedos C. From pediatric to adult care: strategic evaluation of a transition program for patients with osteogenesis imperfecta. Biomed Central Health Serv Res. 2014;14:489. doi:10.1186/s12913-014-0489-1.

    Article  Google Scholar 

  30. Shapiro JR, German-Lee EL. Osteogenesis imperfecta: effecting the transition from adolescent to adult medical care. J Musculoskelet Neuronal Interact. 2012;12(1):24–7.

    CAS  PubMed  Google Scholar 

  31. Adami S, Gatti D, Colapiero F, Fracassi F, Braga V, Rossini M. Intravenous neridronate in adult with osteogenesis imperfecta. J Bone Miner Res. 2003;18(1):126–30.

    Article  CAS  PubMed  Google Scholar 

  32. Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina-Granade G, Duboeuf F, et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res. 2006;21(2):300–6.

    Article  CAS  PubMed  Google Scholar 

  33. Pavon de Paz I, Iglesias Bolanos P, Duran Martinez M, Olivar Roldan J, Guijarro De Armas G, Parra Garcia JI. Effects of zoledronic acid in adults with osteogenesis imperfecta. Endocrinol Nutr. 2010;57(6):245–50.

    Article  PubMed  Google Scholar 

  34. Shapiro JR, Thompson CB, Wu Y, Nunes M, Gillenj C. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. Calcif Tissue Int. 2010;87(2):120–9.

    Article  CAS  PubMed  Google Scholar 

  35. Bradbury LA, Barlow S, Geoghegan F, Hannon RA, Stuckey SL, Wass JA, et al. Risedronate in adults with osteogenesis imperfecta type 1 results in increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporos Int. 2012;223(1):285–94.

    Article  Google Scholar 

  36. Bishop NJ, Walsh JS. Osteogenesis imperfecta in adults. J Clin Invest. 2014;124(2):476–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Orwell ES, Shapiro J, Veith S, Wang Y, Lapidus J, Vanek C, et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest. 2014;142(2):491–8.

    Google Scholar 

  38. Lindahl K, Lindahl B, Ljunggren O, Kindmark A. Treatment of osteogenesis imperfecta in adults. Eur J Endocrinol. 2014;171(2):R79–90. doi:10.1530/EJE-14-0017.

    Article  CAS  PubMed  Google Scholar 

  39. van Dijk FS, Cobben JM, Kariminejad A, Maugeri A, Nikkeles PGJ, van Rijn RR. Osteogenesis imperfecta: a review with clinical examples. Mol Syndromol. 2011;2(1):1–20. doi:10.1159/00033228.

    PubMed  PubMed Central  Google Scholar 

  40. Ellis JA, Munro JE, Ponsonby AL. Possible environmental determinants of juvenile idiopathic arthritis. Rheumatology. 2010;49(3):411–25.

    Article  PubMed  Google Scholar 

  41. Horton DB, Scott FY, Haynes K, Putt ME, Rose CD, Lewis JD, et al. Antibiotic exposure and juvenile idiopathic arthritis: a case-control study. Pediatrics. 2015;136(2):e333–43.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Rheumatology Network. Early identification of juvenile idiopathic arthritis. 2010. http://www.rheumatologynetwork.com/juvenile-arthritis/early-identification-juvenile-idiopathic-arthritis. Accessed 5 Sept 2015.

  43. Weiss JE, Ilowite NT. Juvenile idiopathic arthritis. Rheum Dis Clin North Am. 2007;33(3):441–70. vi.

    Article  PubMed  Google Scholar 

  44. Espinosa M, Gottlieb BS. Juvenile idiopathic arthritis. Pediatr Rev. 2012;33(7):303–12.

    Article  PubMed  Google Scholar 

  45. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Juvenile arthritis: questions and answers about juvenile arthritis. 2015. http://www.niams.nih.gov/Health_Info/Juv_Arthritis/#5. Accessed 28 Dec 2015.

  46. Kim KH, Kim DS. Juvenile idiopathic arthritis: diagnosis and different diagnosis. Korean J Pediatr. 2010;53(1212):931–5.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Stoll MJ, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J. 2014. doi:10.1186/1546-0096-12-13.

    PubMed  PubMed Central  Google Scholar 

  48. NHS England Clinical Reference Group for Paediatric Medicine. NHS England clinical commissioning policy statement: biologic therapies or the treatment of juvenile idiopathic arthritis. NHS England (e-format). 2015. https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/10/e03pd-bio-therapies-jia-oct15.pdf. Accessed 13 Dec 2015.

  49. Beukelman T, Haynes K, Curtis JR, Xie F, Cen L, Bemrich-Stolz CJ, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64(4):1263–71.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Kim SC, Pope J. Juvenile idiopathic arthritis: stretching and strengthening exercises. Scand J Rheumatol. 2012;28(1):19–26.

    Google Scholar 

  51. Takken T, Van Brussel M, Engelbart RH, van der Net J, Kuis H, Helders PJM. Exercise therapy in juvenile idiopathic arthritis. Cochrane Database Syst Rev. 2008. doi:10.1002/144651858.CD005954.pub2.

    PubMed  Google Scholar 

  52. Takken T, van der Net J, Helders PJM. Relationship between functionality and physical fitness in juvenile idiopathic arthritis patients. Scand J Rheumatol. 2003;32(3):174–8.

    Article  CAS  PubMed  Google Scholar 

  53. Epps H, Ginnelly L, Utley M, Southwood T, Gallivan S, Sculpher M, et al. Is hydrotherapy cost effective? A randomized controlled trial of combined hydrotherapy programmes compared with physiotherapy land techniques in children with juvenile idiopathic arthritis. Health Technol Assess. 2005;9(39):iii–iv. ix-x: 1–59.

    Article  CAS  PubMed  Google Scholar 

  54. Takken T, van der Net J, Heiders PJM. Physical activity and health related physical fitness in children with juvenile idiopathic arthritis. Ann Rheum Dis. 2003. doi:10.1136/ard.62.9.885.

    PubMed  PubMed Central  Google Scholar 

  55. Sandstedt E, Fasth A, Eek MN, Beckung E. Muscle strength, physical fitness and well-being in children and adolescents with juvenile idiopathic arthritis and the effect of an exercise programme: a randomized controlled trial. Pediatr Rheumatol. 2013;11(1):7. doi:10.1186/1546-0096-11-7.

    Article  Google Scholar 

  56. McDonagh JE. Osteoporosis in juvenile idiopathic arthritis. Curr Opin Rheumatol. 2001;13:399–404.

    Article  CAS  PubMed  Google Scholar 

  57. Pepmueller PH, Cassidy JT, Allen SH, Hillman LS. Bone mineralization and bone mineral metabolism in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1996;39(5):746–57.

    Article  CAS  PubMed  Google Scholar 

  58. Roth J, Bechtold S, Borte G, Dressler F, Girschick HJ, Borte M. Osteoporosis in juvenile idiopathic arthritis-a practical approach to diagnosis and therapy. Eur J Pediatr. 2007. doi:10.1007/s00431-007-0484-1.

    Google Scholar 

  59. Hind K, Burrows M. Weight-bearing exercise and bone mineral accrual in children and adolescents: a review of controlled trials. Bone. 2007;40(1):14–27.

    Article  CAS  PubMed  Google Scholar 

  60. Klepper S. Making the case for exercise in children with juvenile idiopathic arthritis: what we know and where do we go from here. Arthritis Care Res. 2007;57(6):887–90.

    Article  Google Scholar 

  61. Hochberg Z, Bereket A, Davenport M, Delemarre-van de Waal HA, De Schepper J, Levine MA, et al. Consensus development for the supplementation of vitamin D in childhood and adolescence. Horm Res. 2002;58(1):39–51.

    CAS  PubMed  Google Scholar 

  62. Noguera A, Ros JB, Pavia C, Alcover E, Valis C, Villaronga M, et al. Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children. J Pediatr Endocrinol Metab. 2003;16(4):529–36.

    Article  CAS  PubMed  Google Scholar 

  63. Lepore L, Pennesi M, Barbi E, Pozzi R. Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin Exp Rheumatol. 1991;9 Suppl 6:33–5.

    PubMed  Google Scholar 

  64. Thornton J, Ashcroft D, O’Neill T, Elliott R, Adams J, Robert C, et al. A systematic review of the effectiveness of strategies for reducing fracture risk in children with juvenile idiopathic arthritis with additional data on long-term risk of fracture and cost of disease management. Health Technol Assess. 2008;12:41–7.

    Article  Google Scholar 

  65. Nigrovic PA, White PH. Care of the adult with juvenile rheumatoid arthritis. Arthritis Rheum. 2006;55(2):2208–16.

    Article  Google Scholar 

  66. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: social function, relationships and sexual activity. Rheumatology (Oxford). 2002;41(12):1440–3.

    Article  CAS  Google Scholar 

  67. Scott RD. Total hip and knee arthroplasty in juvenile rheumatoid arthritis. Clin Orthop Relat Res. 1990;259:83–91.

    Google Scholar 

  68. Kotaniemi K, Arkela-Kautiainen M, Haapasaari J, Leirisalo-Repo M. Uveitis in young adults with juvenile idiopathic arthritis: a clinical evaluation of 123 patients. Ann Rheum Dis. 2005. doi:10.1136/ard.2004.026955.

    PubMed  Google Scholar 

  69. Zak M, Fledelius H, Karup F. Ocular complications and visual outcome in juvenile chronic arthritis: a 25-year follow-up study. Acta Ophthalmol Scand. 2003;81(3):211–5.

    Article  PubMed  Google Scholar 

  70. Food and Drug Administration. Biologics: new treatments for juvenile arthritis. Silver Spring: Food and Drug Administration; 2014. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm403578.htm. Accessed 27 Dec 2015.

  71. McErlane F, Foster H, Davies R, Lunt M, Watson KD, Symmons DPM, et al. Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology. 2013;52(120):1905–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Selvaag AM, Aulie HA, Lilleby V, Flate B. Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2014-206034.

    Google Scholar 

  73. Zak M, Hassager C, Lovell DJ, Nielson S, Henderson CJ, Pedersen FK. Assessment of bone mineral density in adults with a history of juvenile chronic arthritis. Arthritis Rheum. 1999;42(4):790–8.

    Article  CAS  PubMed  Google Scholar 

  74. French AR, Mason T, Nelson AM, Crowson CS, O’Fallon WM, Khosla S, et al. Osteopenia in adults with a history of juvenile rheumatoid arthritis. A population-based study. J Rheumatol. 2002;29(5):1065–70.

    PubMed  Google Scholar 

  75. Haugen M, Lien G, Flato B, Kyammen J, Vinje, Sorskaar D, et al. Young adults with juvenile arthritis in remission attain normal peak bone mass at the lumbar spine and forearm. Arthritis Rheum. 2000;43(7):1504–10.

    Article  CAS  PubMed  Google Scholar 

  76. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton III LJ. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Min Res. 2004;19(6):893–9.

    Article  Google Scholar 

  77. Maresova KB. Secondary osteoporosis in patients with juvenile idiopathic arthritis. J Osteoporos. 2011. doi:10.4061/2011/569417.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rehabilitation Medicine, Thomas Jefferson University, Philadelphia, PA, USA

    Christina V. Oleson

Authors
  1. Christina V. Oleson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christina V. Oleson .

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Oleson, C.V. (2017). Primary Osteoporosis in Conditions of Pediatric Onset. In: Osteoporosis Rehabilitation. Springer, Cham. https://doi.org/10.1007/978-3-319-45084-1_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-45084-1_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-45082-7

  • Online ISBN: 978-3-319-45084-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation